ASND Ascendis Pharma A/S

+6.50  (23%)
Previous Close 27.74
Open 40.20
Price To book 7.41
Market Cap 1112887483
Shares 32,502,555
Volume 3,022,789
Short Ratio 3.62
Av. Daily Volume 95,929

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated August 2016. Enrollment to be completed 4Q 2017.
Growth hormone deficiency in children

Latest News

  1. This Biotech Is Ascending To Record Highs After Rival's Failure
  2. Is Ascendis Pharma A/S (ASND) Thriving Or Barely Surviving In The Healthcare Sector?
  3. Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
  4. Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  5. Edited Transcript of ASND earnings conference call or presentation 18-Aug-17 12:00pm GMT
  6. Corporate News Blog - Ritter Pharma Announces Phase-3 Plans After End of Phase-2 Meeting with the FDA on RP-G28 for Lactose Intolerance
  7. Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
  8. Ascendis Pharma A/S Announces Upcoming Investor Presentations
  9. Ascendis Pharma A/S Announces Second Quarter 2017 Financial Results Conference Call on August 18
  10. Corporate News Blog - Cellect Biotech Gets Patent for Method of Use for Flagship Technology - ApoGraft(TM)
  11. Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  12. Ascendis Pharma A/S Reports First Quarter 2017 Financial Results
  13. Ascendis Pharma A/S Announces First Quarter 2017 Financial Results Conference Call on May 23
  14. Ascendis Pharma A/S Showcases New Data on Rare Disease Product Pipeline at ENDO 2017
  15. Ascendis Pharma A/S Announces Updated Time for April 3 Conference Call to Review ENDO 2017 Data
  16. Ascendis Pharma A/S Announces Conference Call and Webcast to Review Data at ENDO 2017 on April 3
  17. Ascendis Pharma A/S Reports Full Year 2016 Financial Results
  18. Ascendis Pharma A/S Announces Year-End 2016 Financial Results Conference Call on March 22
  19. Ascendis Pharma A/S Announces Multiple Poster Presentations at ENDO 2017